Jeffrey Kramer
Analyst · Sidoti. Your line is open
Thank you, Mark, and good morning everyone. Yesterday, we reported second quarter results with sales up 6% to $270 million and adjusted EPS up 13% to $0.99 a share. We were pleased to deliver good performance despite significant inflationary pressures and expenses related to our AMS site consolidation. For the quarter, the key takeaways are solid sales growth coupled with good manufacturing operations driving top and bottom line performance in EP and continued strong organic sales growth in AMS offsetting short-term expenses acquired to realize the Conwed synergies, and finally a positive lift from lower taxes. Year-to-date free cash flow was tracking as planned toward our expectation of exceeding $100 million in 2018. AMS delivered 5% sales growth with no acquisitions benefit, which I'd like to highlight, was on top of an already strong second quarter last year when organic growth was 10%. Overall, performance was propelled by strong growth in both filtration and medical sales, while the transportation segment was down slightly due to a difficult year-over-year comparison. The business remained solidly positive year-to-date. Our infrastructure, construction and industrial sale segments were flat versus last year. To share more detail, our filtration business performed well across its sub-segments. RO water filtration was up double digits, as we continue to benefit from the return of the replenishment cycle and our customers maintain a bullish outlook for the remainder of the year. After being somewhat guarded on this expected rebound at the end of last year, our confidence in the sustainability of this near-term trend has increased. We also saw continued momentum in process filtration driven mainly by gains in semiconductor manufacture and use of our products in heavy equipment, such as components of fuel and hydraulic liquid filters. In medical, we continued its strong momentum from the first quarter. While nearly half of this business is related to the more mature consumer finger bandage category, we also offer variety of specialty products that illustrate our portfolio breadth, which have been the drivers of our 2018 growth thus far. These include niche products like films for medical packaging, hospital IV and Ostomy bags, advanced wound care applications, and air filtration materials for face mask typically popular in Asia. Our transportation business delivered healthy sales, but compared to an extremely strong 2Q 2017 we are down slightly. Year-to-date, this market remained solidly positive and our order backlog and customer indication support a robust outlook for these surface protection films. In our infrastructure and construction business, recall that earlier this year we were affected by severe winter conditions in some of our key markets. These conditions have now moderated and sales have begun to recover with positive go forward expectations. Despite solid sales performance, we did report a contraction of our year-over-year unit margins. We continue to incur expected cost as we get closer to a final exit of Austin site later this year. Similar to the first quarter, the higher costs associated with this site accounted for most of the adjusted segment margin decline. However, we expect significant savings in the fourth quarter when we realize the full synergy from closing this facility. We remain on target for this important project. A second, but smaller issue is polypropylene costs, which remain elevated. We have increased prices on polypropylene based netting products and we estimate we have recovered a majority of the higher cost impact this quarter. We continue to evaluate and execute price increases and have also begun implementing a freight surcharge in response to rising trucking costs in the U.S. Also sales remain strong, our new Chinese manufacturing site is fully up and performing well and we remain on plan with our new European film line. While resin costs continue to rise and pose a challenge to margins, we are in the homestretch of closing the Austin site and to realizing our Conwed related synergy plan. Moving to Engineered Paper, second quarter sales grew 6% with good price mix performance and currency overcoming of 4% volume decline. Of note, the year-to-date segment volume decline was 1% showing relative stability despite some of the quarter-to-quarter variations. In the quarter, we delivered increased Cigarette Paper volumes and high growth in our heat-not-burn business offset by a decline in traditional RTL products. As shown, we remain positive on this segment, but will expect to see some variance in customer order patterns at the scale of their supply chains and learn more about consumer preferences across the globe. One significant headwind remains elevated pulp costs. As many paper suppliers are reporting, the global supply demand for these – balance for these materials is tight, we are actively raising prices were contracts permit, but we should note there is some lag on several customer agreements. As a result, while operating profit dollars increased, margins were slightly lower than last year. We performed well in the quarter from a manufacturing perspective with productivity gains delivering a solid offset to rising input costs and we continue to push hard to counterbalance inflationary pressures with efficiencies. Just a few additional comments on heat-not-burn, sales were again up significantly over the last year and we continue to have very collaborative development discussions with our customers. This area has become a focal point in the industry with heated tobacco product growth attracting the spotlight from the investment community. Recently, announcements have highlighted our earlier comments that these new applications can be lumping in initial phases of introduction. Our growth remains generally in line with our original expectation. The innovation in this category is very exciting and we remain bullish on its long-term prospects as the industry sorts through capacity planning, pricing, consumer preferences, and regulations. We view the product as part of a multiplying plan to drive relative stability in our EP business. I will now turn the call over to Andy.